Results 81 to 90 of about 1,579,650 (291)

Overview of PD-L1 expression by different anti-PD-L1 clones across the different subtypes of lymphomas.

open access: yes, 2016
Overview of PD-L1 expression by different anti-PD-L1 clones across the different subtypes of lymphomas.
Jeffery Kimbrough (3353009)   +8 more
core   +1 more source

PD-L1 expression on platelets.

open access: yes, 2021
Whole Blood, a pure platelet pellet, and platelet poor plasma from two patients, one with positive platelet PD-L1 (A) and one with negative platelet PD-L1 (D), was processed through CellSearch® in parallel with PD-L1 staining in the 4th channel.
James M. Rae (7876037)   +15 more
core   +1 more source

A Two‐Stage Questionnaire and Actigraphy Screening for iRBD in a Multicenter Retrospective Cohort

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Isolated rapid‐eye‐movement sleep behavior disorder is a prodromal marker of synucleinopathies. However, most cases remain undiagnosed due to the insufficient predictive value of questionnaires and limited access to confirmatory video‐polysomnography. We assessed a two‐stage screening strategy combining a brief questionnaire on rapid‐
Caleb A. Massimi   +17 more
wiley   +1 more source

PD-L1 expression is increased in a subset of basal type breast cancer cells. [PDF]

open access: yesPLoS ONE, 2014
Tumor cells express programmed death ligand 1 (PD-L1) and is a key immune evasion mechanism. PD-L1 expression in multiple breast cancer cell lines was evaluated to identify intrinsic differences that affect their potential for immune evasion.PD-L1 ...
Hatem Soliman   +2 more
doaj   +1 more source

Standardization of PD-L1 immunohistochemistry [PDF]

open access: yesModern Pathology, 2022
Sandra Martinez-Morilla   +2 more
openaire   +2 more sources

Integrated PANoptosis Profiling Identifies Immunosuppressive Subtypes and a Prognostic Signature With Functional Validation of MLKL in Glioblastoma

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The prognosis of glioblastoma (GBM) remains highly unfavorable, largely due to high tumor heterogeneity and an immunosuppressive microenvironment. However, the functional role of PANoptosis in this context is poorly understood. Methods Patients were stratified via K‐means clustering. A risk score model was constructed using prognosis‐
Langfei Tian   +6 more
wiley   +1 more source

Regulation of PD-L1 expression in the tumor microenvironment

open access: yesJournal of Hematology & Oncology, 2021
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune
Ming Yi   +4 more
doaj   +1 more source

Ion‐Reconfigurable “N”‐Shaped Antiambipolar Behavior in Organic Electrochemical Transistors

open access: yesAdvanced Materials, EarlyView.
A unique N‐shaped negative differential transconductance (NDT) characteristics is demonstrated in single‐polymer organic electrochemical transistors through a sequential doping–redox–doping process driven by iodide ions. This redox‐driven mechanism enables low‐voltage, ion‐controlled reconfigurability and tunable current modulation, allowing seamless ...
Debdatta Panigrahi   +11 more
wiley   +1 more source

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells

open access: yesCell Reports, 2018
Summary: The PD-1 pathway, consisting of the co-inhibitory receptor PD-1 on T cells and its ligand (PD-L1) on antigen-presenting cells (APCs), is a major mechanism of tumor immune evasion.
Yunlong Zhao   +5 more
doaj   +1 more source

CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. [PDF]

open access: yes, 2016
Immunomodulatory therapies, targeting the immune checkpoint receptor-ligand complex PD-1/PD-L1 have shown promising results in early phase clinical trials in solid malignancies, including carcinomas of the head and neck.
Pfarr, Nicole   +30 more
core   +2 more sources

Home - About - Disclaimer - Privacy